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Summary: The liver is involved in the turnover of fibronectin in two different ways: hepatic synthesis contrib-
utes substantially to the plasma fibronectin pool, while Kupffer-ce\\s, performing an important role of the
reticuloendothelial System, remove fibronectin opsonized materi^l from the circulation.
In 45 patients with histologically confirmed liver cirrhosis and six patients with acute liver failure due to
intoxication we determined fibronectin concentration in plasma by electroimmunoassay and additionally mea-
sured factor VHI-related antigen, which is a large glycoprotein not synthesized in the liver.
Fibronectin levels in plasma were decreased in liver cirrhosis. This decrease was correlated with the extent of
porto-caval collateral circulation. Very low levels were found in patients with acute liver failure. Factor VIII-
related antigen levels were greatly increased äs a function of the hepatic insufficiency. Between both parame-
ters there was a significant inverse correlation. It is concluded that the simultaneous determination of both
proteins provides reliable Information about the remaining liver function.
Fibronectin und Faktor Vlll-assoziiertes Antigen bei Lebercirrhose und akutem Leberversagen
Zusammenfassung: Die Leber ist am Umsatz des Fibronectin im Plasma in zweierlei Hinsicht beteiligt: Die
Fibronectinsynthese in der Leber liefert einen Teil des Fibronectins im Plasma, und /p/jfer-Zellen entfernen
als ein wichtiger Bestandteil des reticuloendothelialen Systems durch Fibronectin der Phagozytose zugänglich
gemachtes Material aus der Blutbahn.
Wir untersuchten 45 Patienten mit der histologisch gesicherten Diagnose Lebercirrhose und sechs Patienten
mit akutem Leberversagen nach Vergiftung. Fibronectin und Faktor Vlll-assoziiertes Antigen, bei dem es
sich ebenfalls um ein großes Glycoprotein handelt, das aber nicht in der Leber synthetisiert wird, wurden bei
diesen Patienten im Plasma mittels Elektroimmunoassay bestimmt.
Fibronectin war im Plasma der Patienten mit Lebercirrhose vermindert. Diese Verminderung korrelierte mit
dem Ausmaß eines porto-cavalen Shuntkreislaufs. Sehr niedrige Werte wurden bei akutem Leberversagen
gemessen. Hingegen waren die Konzentrationen von Faktor VHI-assoziiertem Antigen im Plasma stark er-
höht in Abhängigkeit von der Schwere der Erkrankung. Zwischen den Konzentrationen beider Glycoproteine
im Plasma bestand eine umgekehrte Korrelation. Offensichtlich ist die gleichzeitige Bestimmung beider
Kenngrößen geeignet, um Informationen über die verbliebene Leberfunktion der Patienten zu erhalten.
in interstitial connective tissue and in or close to
u n basenient membranes. Due to its specific binding to
Fibronectin is an adhesive and opsonic glycoprotein. fibrin, Collagen, heparin and bacteria etc., its func-
In its soluble form it is present in plasma and other tion has been compared to that of a molecular glue
. body fluids, whereas in its insoluble form it is found (1).
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One of the important functions of fibronectin is that
it acts äs a mediator of phagocytosis by macrophages
and endothelial cells of the reticuloendothelial sys-
tem (2). Thus the term "az-surface binding opsonic
glycoprotein" has also been used to characterize its
function. A deficiency of plasma fibronectin follow-
ing trauma, burn and sepsis has been correlated with
systemic failure of reticuloendothelial System func-
tion (3, 4). This, and the fact that fibronectin is syn-
thesized in the liver (5), caused us to investigate
plasma fibronectin levels in patients with liver fail-
ure. Simultaneously, the related large glycoprotein
factor Vlll-related antigen was measured, which in
contrast to fibronectin, is not synthesized in the liver
(6), but is said to be a reliable marker for the clear-
ance function of the reticuloendothelial System (7).
Materials and Methods
Pat ien t s
Forty-five patients with histologically confirmed liver cirrhosis
were subdivided according to the severity of hepatic insufficiency
using the extent of the porto-caval collateral circulation. This pa-
rameter was evaluated by laparoscopy and radiology.
Elec t ro immunoassay
Using the procedure of Laurell (8), electroimmunoassay was per-
formed in a barbital buffer System (pH 8.6, ionic strength 0.02) on
5 cm square plates. An agarose gel 10 g/l was used, containing 6.6
ml/l anti-human fibronectin and anti-factor Vlll-related protein,
respectively. Four of the plates were run on a thermostated dish.
At l cm intervals, wells 3 mm in diameter were cut into the gel
and filled with 7 of plasma dilutions to be assäyed. Electro-
phoresis was performed at 6 V/cm for 18 hours at 17 °C. The gels
were then washed, dried and finally stained with Coomassie bril-
liant blue. A reference curve was set up using dilutions of the
protein Standard plasma with the known fibronectin con-
centration. For factor Vlll-related antigen a pool of ten plasmas
of healthy subjects served äs feference. Our experience with this
method resulted in a Standard deviation of ±8% and ±10.6% for
factor Vlll-related antigen and fibronectin, respectively, when the
assays of the same sample were done on 8 different days.
Crossed-immunoelectrophoresis
Crossed-immunoelectrophoresis was performed on 10 cm square
plates, according to Clarke & Freeman (9); the first dimension at
12 V/cm for 80 minutes and second dimension at 6 V/cm for 15
hours. In the second dimension, the antiserum concentration of
anti-fibronectin and anti-factpr VHI-related protein was 6.6 ml/l
agarose gel.
Statistical analysis
Means ± Standard deviation were computed from all data. Levels
of significance were evaluated according to Studenfs t-test.
Group I, n = 10:
Patients without signs of porto-caval collateral circulation;
Group II, n = 10:
Patients with porto-caval shunts: oesophageal varices, splenome-
galy, reperfused umbilical veins and congested veins in ligamen-
tum teres and ligamentum falciforme, äs well äs in the omentum
maius;
Group III, n = 25:
Patients with signs of decompensated liver cirrhosis (e. g. ascites
or liver coma).
A further group consisted of 6 patients with acute liver failure due
to intoxication. Thirty-five healthy persons with no history of liver
disease (23 male, 12 female) and with an age distribution between
18 and 82 served äs the control group.
Collection of samples
Venous blood was collected with sodium citrate äs the anticoagu-
lant. After centrifugation at 5000 g for 20 minutes, plasma was
stored at -34 °C until used.
Antisera
Anti-fibronectin serum from rabbits, anti-antihaemophilic globül-
in (anti-factor VIII) related protein serum from rabbits, and pro-
tein Standard plasma with a fibronectin concentration of 250 mg/1
were obtained from Behringwerke AG, Marburg, West Germany.
Results
The concentration of fibronectin^ in plasma of pa-
tients with liver cirrhosis was significantly decreased
äs soon äs there were any signs of a porto-caval col-
lateral circulation (tab. 1). There were also signifi-
cant differences between the cirrhosis subgroups.
The lowest plasma fibronectin levels were found in
patients with acute liver failure.
Factor Vlll-related antigen behaved quite different-
ly. Its concentration was increased up to 20-fold in
patients with cirrhosis, this increase being a function
of the severity of the disease, namely from subgroups
I to III (tab. 2). Very high levels were also found in
patients with acute liver failure.
Between the fibronectin and the factor Vlll-related
antigen plasma concentrations there was a significant
negative correlation (fig. 1). We used crossed-immu-
noelectrophoresis with both antisera in the second
dimension to demonstrate this relationship (fig. 2),
thereby confirming that the high factor Vlll-related
antigen concentrations found in the electroimmu-
noassay were not due to a modified-electrophoretic
mobility of an altered protein. *
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Tab. 1. Plasma fibronectin levels in patients with liver disease.
Fibronectin concentrations were measured by electroim-
munoassay. Group l consisted of healthy persons without
any signs or history of liver disease. The patients with
liver cirrhosis were subgrouped according to the extent of
porto-caval shunt. Acute liver failure in patients of group
5 was caused by intoxication. Mean values ± Standard
deviation are given. Levels of significance were calculated














a) p < 0.005 compared to Group l
b) p < 0.005 compared to Group 2









Tab. 2. Factor VHI-related antigen in plasma of patients with
liver disease.
Factor VHI-related antigen was determined by elec-
troimmunoassay in the same patients s in table 1. Be-
cause of the lack of a suitable Standard, factor VHI-relat-
ed antigen concentration in a plasma pool of healthy do-
. nors was set to 1.00. Mean values ± Standard deviation
are given. Levels of significance were calculated accord-
ing to Student'* t-test,
Patient group Number Factor VIII-




a) p < 0.001 compared to Group l
b) p < 0.001 compared to Group 2
c)
d)
p < 0.005 compared to Group 2
























0.0 l · J S ι
50 100 150 200 250 300 350 400
Fibronectin (μ g/m l ]
Fig. 1. Statistical evaluation of the conrelation between the con-
centrations of fibronectin and factor Vlll-related antigen
in the plasgias of the patients in this study.
n = 86; r = -0.3758; y = 15.88 - 0.0434x; p < 0.001.
Discussion
Production sites of fibronectin in vivo are considered
to be fibroblasts (10), vascular endothelial cells (11),
and hepatocytes (12). A recent study pn fibronectin
synthesis in the perf sed liver (5) indicates that he-
patic synthesis contributes substantially to the plas-
ma fibronectin pool. One property of the plasma fi-
bronectin is that it can bind to a large number of
particles and macromolecules and mediate their op-
sonization by cells of the reticuloendothelial System.
A deficiency of plasma fibronectin, s well s a de-
pression of the reticuloendothelial System may im-
pair its clearance function (13). This is observed in
septicaemia, where the reticuloendothelial System is
overloaded and the plasma fibronectin concentration
is reduced (14). In this case a Substitution of fibro-
nectin was shown to improve the clinical state of the
patients (15). Similar conditions may occur in pa-
tients with liver cirrhosis because the liver synthes-
izes patt of the fibronectin, and Kupffer cells repre-
sent an important part of the reticuloendothelial sys-
tem.
As presented in table l, there was a significant de-
cline of plasma fibronectin s soon s signs of a por-
to-caval shunt were found. The most striking reduc-
tion occurred in patients with acute liver failure, due
to intoxication. In these patients haemostatic abnor-
malities of disseininated intravascular coagulation
were also registered, which may have contributed to
the drastic fall of fibronectin concentration. Our re-
sults regarding the cirrhosis patients seem to be in
contradiction to earlier publications where elevated
fibronectin levels were described (16), but the stages
of liver cirrhosis we examined were different. We
only found reduced levels of fibronectin in advanced
disease, and all patients had an insufficiency of he-
patic function. One explanation for the reduced fi-
bronectin levels takes into consideration decreased
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Fig. 2. Crossed-immunoelectrophoresis of patients with liver disease.
In the second dimension anti-fibronectin and anti-factor VHI-related antigen serum was present. From left to right a plasma frorn
the cirrhosis stage I, stage III-group and from a patient with severe acute liver failure are shown. In addition to the high fibronec-
tin peak, the slower migrating factor VHI-related antigen precipitate is seen to increase äs the disease becomes mofe severe. The
patient with acute liver failure showed the lowest fibronectin concentration of all examined patients, so that it was not even seen
by this technique.
hepatic synthesis although there was a poor correla-
tion to plasma albumin in our patients. Since it has
been shown that fibronectin is susceptible to limited
proteolysis by plasmin (17), an increased catabolism
of fibronectin due to an accelerated fibrinolysis may
have contributed to the reduced plasma levels.
Plasma levels of factor VHI-related antigen in-
creased äs a function of the severity of liver cirrhosis.
Because this protein is not synthesized in the liver
(6), we suppose that its increased plasma concentra-
tion reflects the depressed clearance function of the
liver reticuloendothelial System (7). The possibility
that this increase could be due to false results ob-
tained by LaureWs technique caused by a modified
mobility of an altered protein (18), was ruled out by
using the two dimensional immunoelectrophoresis
(fig.2).
The simultaneous determination of the two related
glycoproteins, fibronectin and factor Vltt-related
antigen, in patients with liver disease inay supply In-
formation about the synthesis and catabolism of fi-
bronectin and the clearance function of the liver reti-
culoendothelial system. In cases with hepatic insuffi-
ciency and septic complications a Substitution of fi-
bronectin should be taken into consideration.
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